Regen Biopharma receives U.S. patent for mRNA-based cancer vaccine technology

Regen BioPharma Inc

USPTO issued Patent No. 11,090,332 B2 on August 17, 2021, for "Antigen Specific MRNA Cellular Cancer Vaccines".
The invention covers modified mRNA encoding immunogenic epitopes, e.g., survivin-derived peptides, to induce intracellular antigen production.
Patent aims to expand epitope repertoire presented to adaptive immune system, improving likelihood of successful immunity induction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.